Insmed Incorporated (INSM) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 21.94B USD. 52-week range 90.39 to 212.75 USD. Data as of 2026-10-09.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor ...